Research Papers:

Diagnostic accuracy of urine HE4 in patients with ovarian cancer: a meta-analysis

Meng-Meng Jia _, Jie Deng, Xiao-lin Cheng, Zhen Yan, Qing-Chun Li, Ying-Ying Xing, Dong-Mei Fan and Xiao-Yu Tian

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9660-9671. https://doi.org/10.18632/oncotarget.14173

Metrics: PDF 2403 views  |   HTML 1988 views  |   ?  


Meng-Meng Jia1, Jie Deng1, Xiao-lin Cheng1, Zhen Yan1, Qing-Chun Li1, Ying-Ying Xing1, Dong-Mei Fan1, Xiao-Yu Tian1

1Department of Obstetrics and Gynecology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China

Correspondence to:

Xiao-Yu Tian, email: tianxiaoyu816@163.com

Keywords: HE4, tumour marker, ovarian cancer, diagnosis, meta-analysis

Received: September 09, 2016    Accepted: November 23, 2016    Published: December 26, 2016


Urine HE4 has been reported as the potential novel diagnostic biomarker for ovarian cancer in several studies, but their results were inconsistent. Therefore, we conducted a systematic analysis to evaluate the diagnostic value of urine HE4 in detecting ovarian cancer. A comprehensive electronic and manual search was conducted for relevant literatures through several databases up to May 5, 2016. The quality of the studies included in the systematic review was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. All analyses were conducted using Meta-DiSc 1.4 and STATA 12.0 software. A total of seven publications were included in this study, and these studies included 413 ovarian cancer patients and 573 controls. The summary estimates were: sensitivity 0.76 (95% confidence interval [CI]: 0.72–0.80), specificity 0.92 (95% CI: 0.89–0.94), positive likelihood ratio 8.39 (95%CI: 4.81–14.63), negative likelihood ratio 0.23 (95% CI: 0.13–0.39), diagnostic odds ratio 37.90 (95% CI: 18.69–76.83), and area under the curve 0.93. According to our results, urine HE4 has greater diagnostic value in detecting ovarian cancer. In addition, considering the high heterogeneity, further research studies with more well-designed and large sample sizes are needed in the future.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14173